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ABSTRACT
Background: The aim of this study was to
evaluate the predictive performance of the
INCREMENT-CPE (ICS), Pitt bacteremia score
(PBS) and qPitt for mortality among patients
treated with ceftazidime–avibactam for carbapenem-resistant Enterobacteriaceae (CRE)
infections.
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Methods: Retrospective, multicenter, cohort
study of patients with CRE infections treated
with ceftazidime–avibactam between 2015 and
2019. The primary outcome was 30-day allcause mortality. Predictive performance was
determined by assessing discrimination, calibration and precision.
Results: In total, 109 patients were included.
Thirty-day mortality occurred in 18 (16.5%)
patients. There were no significant differences
in discrimination of the three scores [area under
the curve (AUC) ICS 0.7039, 95% CI
0.5848–0.8230,
PBS
0.6893,
95%
CI
0.5709–0.8076, and qPitt 0.6847, 95% CI
0.5671–0.8023; P [ 0.05 all pairwise comparisons]. All scores showed adequate calibration
and precision. When dichotomized at the
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optimal cut-points of 11, 3, and 2 for the ICS,
PBS, and qPitt, respectively, all scores had
NPV [ 90% at the expense of low PPV. Patients
in the high-risk groups had a relative risk for
mortality of 3.184 (95% CI 1.35–8.930), 3.068
(95% CI 1.094–8.606), and 2.850 (95% CI
1.016–7.994) for the dichotomized ICS, PBS,
and qPitt, scores respectively. Treatment-related
variables (early active antibiotic therapy, combination antibiotics and renal ceftazidime–avibactam dose adjustment) were not associated
with mortality after controlling for the risk
scores.
Conclusions: In patients treated with ceftazidime–avibactam for CRE infections, mortality risk scores demonstrated variable
performance. Modifications to scoring systems
to more accurately predict outcomes in the era
of novel antibiotics are warranted.
Keywords: Carbapenem-resistant
Enterobacteriaceae;
Ceftazidime–avibactam;
INCREMENT-CPE; Pitt bacteremia
Key Summary Points
The INCREMENT CPE, Pitt Bacteremia and
qPitt scores have recently been validated
in patients with bacteremic and nonbacteremic carbapenem-resistant
Enterobacteriaceae (CRE) infections.
However, these studies included no or few
patients treated with newer anti-CRE
antibiotics.
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In patients treated with
ceftazidime–avibactam for CRE infections,
the mortality risk scores demonstrated
variable performance.
Modifications to scoring systems to more
accurately predict outcomes in the era of
novel antibiotics is warranted.

INTRODUCTION
Enterobacteriaceae are among the most frequent cause of bacterial infections in patients of
all ages in both community and inpatient settings [1]. The remarkable ability of these
organisms to acquire a growing array of mechanisms to evade the activity of broad-spectrum
antibiotics therefore presents a growing challenge. In particular, the emergence and spread
of carbapenem-hydrolyzing beta-lactamases
(carbapenemases) limits our ability to treat
many life-threatening infections [2]. Due to the
well-rehearsed challenges of conducting randomized controlled trials (RCTs) in patients
with carbapenem-resistant Enterobacteriaceae
(CRE) infections, current management strategies are largely informed by observational data
and expert opinion [3]. Observational studies
can provide valuable insight into the real-world
effectiveness of treatment alternatives in circumstances where execution of RCTs is not
feasible. However, because treatment is not
randomly assigned, confounding by indication
may lead to a biased estimate of the treatment
effect. Covariate adjustment is especially
important in CRE studies due to the wide
spectrum of disease severity and underlying
health status of the patients who acquire these
infections, which clearly influences both the
management approach and outcomes. Risk
scores are useful for covariate adjustment in
these circumstances, and they can also facilitate
comparisons of populations across different
studies. Furthermore, some risk scores have
been used clinically to define high-risk subgroups for whom more intensive management
strategies may be targeted [4, 5]. A number of
risk scores have recently been developed and/or
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validated specifically in patients with CRE
infections [4, 6, 7]. The INCREMENT-CPE score
(ICS) was developed to predict 14-day mortality
in patients with carbapenemase-producing
Enterobacteriaceae (CPE) bacteremia [4]. It was
subsequently modified and validated for 30-day
mortality in patients with bacteremic and nonbacteremic CPE infections [6]. The Pitt bacteremia score (PBS) and an abbreviated version
of the PBS, the qPitt, were also recently validated in a large cohort of patients with bacteremic and non-bacteremic CRE infections [7].
Notably, these analyses included no [4, 6] or few
[7] patients treated with newer antibiotics with
activity against CRE. Their performance in the
era of more effective and safer antibiotics [8, 9]
is unclear. Therefore, the objective of this study
was to evaluate the predictive performance of
the ICS, PBS, and qPitt for mortality among
patients with CRE infections treated with
ceftazidime–avibactam.

METHODS
Study Design and Population
This was a secondary analysis of a multicenter,
retrospective, observational, cohort study conducted at six geographically diverse academic
and community medical centers in the U.S.
between May 2015 and February 2019 [10].
Approval was obtained from each participating
center’s Institutional Review Board (IRB) with a
waiver for informed consent (Supplementary
Appendix 1). Wayne State University served as
the master IRB. Pharmacy records were screened
for all patients who received ceftazidime–avibactam between January 2015 and February
2019. Inclusion criteria were: (1) age C 18 years,
(2) receipt of ceftazidime–avibactam for C 72 h,
and (3) CRE infection [10].

Data Collection and Study Definitions
Relevant demographic, clinical, microbiological, and treatment data were extracted from the
electronic medical record (EMR) by study

investigators at each center and entered into a
secure online data collection form [11]. Bacterial identification and antibiotic susceptibilities
were performed by local laboratories according
to standard procedures. CRE was defined by
current US Centers for Disease Control and
Prevention criteria [7]. Ceftazidime–avibactam
susceptibility was determined using disk diffusion or gradient strips, where available. Hospital-acquired CRE infection was defined as the
first CRE-positive culture collected C 48 h after
admission. Sources of infection were based on
physician notes and available clinical, microbiological, and diagnostic data. Where available,
resistance markers were identified by VERIGENE
BC-GN (Luminex, Austin, TX, USA). Infection
onset was defined as the day the index CRE
culture was collected. Early active therapy was
receipt of at least one in vitro active antibiotic
within 48 h of infection onset. Early ceftazidime–avibactam therapy was defined as
ceftazidime–avibactam initiated within 48 h of
infection onset. Ceftazidime–avibactam combination therapy was the receipt of a concomitant
antibiotic
with
Gram-negative
activity
for C 48 h.
The primary outcome was 30-day all-cause
mortality, measured from infection onset. Data
were collected for up to 30 days after discharge
(i.e., from health system outpatient clinics,
rehabilitation centers, emergency departments,
and hospital re-admissions, where available),
and patients discharged before day 30 were
assumed to have survived if death was not documented during this follow-up. The ICS, PBS,
and qPitt were calculated for each patient using
the worst physiological values recorded within
24 h of infection onset. The variables included in
the ICS were severe sepsis/septic shock [12],
PBS C 6, Charlson comorbidity score C 2, and
non-biliary or non-urinary tract source of infection [6]. Scores range from 0 to 15 and patients
with an ICS \ 8 and C 8 have been considered to
be at low and high risk for mortality, respectively
[4, 6]. The PBS is based on five variables: temperature, blood pressure, mechanical ventilation, cardiac arrest, and mental status [13]. The
maximum PBS score is 14, with scores C 4 generally considered to indicate increased risk of
death [7, 13]. qPitt includes the same five
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variables as the PBS, but temperature and mental
status are dichotomized rather than graded [14].
The qPitt ranges from 0 to 5, with scores C 2
indicating increased mortality risk in previous
studies [7, 14]. No patient in our cohort experienced cardiac arrest around infection onset, and
therefore this variable was not included in the
scores.
Statistical Analyses
Descriptive statistics were used to characterize
the cohort. Continuous variables were reported
as medians (interquartile ranges, IQR) whereas
categorical variables were expressed as counts
and percentages. Unadjusted comparisons were
performed using Chi squared, Fisher’s exact or
Mann–Whitney U tests, as appropriate.
Scoring system performance was assessed by
determining discrimination, calibration and
precision. Discrimination in this setting refers
to the ability to correctly classify those who
died and those who survived. It was evaluated
by calculating the area under to receiver operating characteristic curve (AUC). An AUC of 1.0
indicates perfect discrimination while a value
0.5 indicates no better than chance [15].
Although there are no universally agreed
thresholds, values C 0.90, C 0.80 and C 0.70
are generally considered to be excellent, good,
and satisfactory, respectively [16, 17]. The nonparametric Delong–Delong test was used for
pairwise AUC comparisons [18].
Calibration refers to agreement between
observed and predicted mortality across deciles
of risk, and was assessed using the Hosmer–Lemeshow goodness-of-fit test [19]. To
account for the smaller sample size, and therefore reduced power to detect a lack of fit, a
conservative P value \ 0.10 was considered to
indicate lack of fit [20].
Precision was measured by calculating the
Brier score (mean squared difference between
observed and predicted mortality). Brier scores
can range from 0 for a perfect model to 0.25 for
a non-informative model with an outcome
incidence of 50% [16, 21].
The performance characteristics of each
score as a binary classification tool were

examined by calculating the sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), positive likelihood ratio
(PLR), and negative likelihood ratio (NLR) at
selected cut-points. The Youden Index
J (J = sensitivity ? specificity - 1 maximized)
was chosen as the most appropriate summary
measure. Modified Poisson regression analysis,
using a robust error variance, was performed to
estimate the relative risk (RR) and 95% confidence intervals for mortality at select cutpoints.
The impact of early active antibiotic therapy,
early ceftazidime–avibactam and combination
therapy was evaluated by Poisson regression
after adjustment for each score individually
modeled as a continuous variable and as a categorical variable dichotomized at the score
corresponding to the maximum J.
Analyses were performed using SAS 9.4 Statistical Software (SAS Institute, Cary, NC, USA)
and SPSS, v.24 (IBM, Armonk, NY, USA). Unless
otherwise stated, a two-tailed p \ 0.05 was
considered statistically significant.

RESULTS
A total of 109 patients were included. The
median age was 63 (53–74) years and 34.9%
were admitted from a skilled nursing facility or
long-term acute care hospital (Table 1). Over
half (54.1%) of patients were in the intensive
care unit (ICU) at infection onset and 16.5%
were admitted during the remainder of their
admission. The most common infection sources
were respiratory (34.9%), intra-abdominal
(21.1%) and urinary (20.2%). Nine (8.3%)
patients had a positive CRE blood culture. A
total of 113 CRE strains were isolated. Klebsiella
pneumoniae was the most commonly identified
pathogen, isolated in 71 (65.1%) patients followed by Escherichia coli in 16 (14.7%) and Enterobacter spp. in 12 (11.0%). Regarding
antimicrobial susceptibility, among K. pneumoniae isolates tested for ceftazidime-avibactam
susceptibility (n = 48), two were resistant,
including one that carried New Delhi metallobeta-lactamase and OXA enzymes.
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Table 1 Baseline patient and infection characteristics stratiﬁed by 30-day mortality
Characteristic

Overall N = 109, n (%) Survivors N = 91,
Non-survivors N = 18,
or median (IQR)
n (%) or median (IQR) n (%) or median (IQR)

Age (years)

63 (53–74)

65 (52–74)

63 (61–73)

28 (22–34)

27 (22–33)

30 (23–39)

Obese (BMI C 30 kg/m )

38 (34.9)

29 (31.9)

18 (50.0)

Male

58 (53.2)

50 (54.9)

8 (44.4)

African American

52 (47.7)

40 (44.0)

12 (66.7)

Caucasian

37 (33.9)

31 (34.1)

6 (33.3)

Latino

6 (5.5)

6 (6.6)

0

Asian

2 (1.8)

2 (2.2)

0

Other

12 (11.0)

12 (13.2)

0

Admission from a skilled nursing
38 (34.9)
facility/long-term acute care hospital

29 (31.9)

9 (50.0)

20 (18.3)

17 (18.7)

3 (16.7)

44 (40.4)

36 (39.6)

8 (44.4)

40 (36.7)

28 (30.8)

12 (66.7)**

End-stage renal disease on dialysis

15 (13.8)

12 (13.2)

3 (16.7)

Liver disease

14 (12.8)

12 (13.2)

2 (11.1)

Cancer

19 (17.4)

15 (16.5)

4 (22.2)

Charlson comorbidity index

4 (2–7)

4 (2–7)

6 (3–7)

Hospital-acquired infection

67 (61.5)

54 (59.3)

13 (72.2)

Intensive care unit at infection onset

59 (54.1)

44 (48.4)

15 (83.3)**

Mechanical ventilation at infection
onset

35 (32.1)

25 (27.5)

10 (55.6)**

Severe sepsis/septic shock at infection
onset

67 (61.5)

52 (57.1)

15 (83.3)**

Positive blood cultures

9 (8.3)

6 (6.6)

3 (16.7)

Respiratory tract

38 (34.9)

29 (31.9)

9 (50.0)

Intra-abdominal

23 (21.1)

21 (23.1)

2 (11.1)

Urinary tract

22 (20.2)

21 (23.1)

1 (5.6)

Skin and soft tissue

7 (6.4)

6 (6.6)

1 (5.6)

Osteoarticular

7 (6.4)

6 (6.6)

1 (5.6)

Primary bacteremia

7 (6.4)

4 (4.4)

3 (16.7)

Other

5 (4.6)

4 (4.4)

1 (5.6)

2

Body mass index (kg/m )
2

Race

Comorbidities
Heart failure
Diabetes mellitus
Chronic respiratory disease

a

Infection source
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Table 1 continued
Characteristic

Overall N = 109, n (%) Survivors N = 91,
Non-survivors N = 18,
or median (IQR)
n (%) or median (IQR) n (%) or median (IQR)

Microbiology
Klebsiella pneumoniae

71 (65.1)

59 (64.8)

12 (66.7)

Escherichia coli

16 (14.7)

15 (16.7)

1 (5.6)

Enterobacter spp.

12 (11.0)

9 (9.9)

3 (16.7)

K. oxytoca

5 (4.6)

3 (3.3)

2 (11.1)

Citrobacter spp.

4 (3.7)

4 (4.4)

0

Serratia marcescens

4 (3.7)

4 (4.4)

0

Proteus mirabilis

1

0

1 (5.6)

Ceftazidime–avibactam renal adjusted 52 (47.7)
dose

39 (42.9)

13 (72.2)**

Active antibiotic before
ceftazidime–avibactam

25 (22.9)

22 (24.2)

3 (16.7)

Hours to active antibioticb

72 (34–103)

74 (43–103)

55 (25–105)

Active antibiotic therapy within 48
hoursb

32 (29.4)

25 (27.5)

7 (38.9)

Hours to ceftazidime–avibactamb

94 (54–145)

95 (55–145)

73 (33–154)

Ceftazidime–avibactam duration
(days)

13 (6–17)

13 (7–18)

8 (4–15)

Ceftazidime–avibactam combination
antibiotic therapy

44 (40.4)

36 (39.6)

8 (44.4)

Aminoglycoside

11 (10.1)

9 (9.9)

2 (11.1)

Polymyxin

10 (9.2)

7 (7.7)

3 (16.7)

Tigecycline

10 (9.2)

9 (9.9)

1 (5.6)

ICS

8 (6–11)

8 (6–11)

11 (8–15)**

PBS

2 (0–5)

2 (0–4)

5 (2–6)**

qPitt

1 (0–2)

1 (0–2)

2 (1–3)**

APACHE II

21 (15–29)

19 (13–24)

30 (21–32)**

SOFA

5 (3–8)

4 (2–7)

10 (7–12)**

Treatment

Risk scores

APACHE Acute Physiology and Chronic Health Evaluation, ICS INCREMENT-CPE score, PBS Pitt bacteremia score,
SOFA Sequential Organ Failure Assessment
**P \ 0.05 survivors vs. non-survivors
a
Chronic obstructive pulmonary disease, asthma, chronic ventilator dependence
b
From index culture collection
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Fig. 1 Area under the curve (AUC) for 30-day mortality
prediction
Overall, 30-day mortality was 16.5%, and
was highest in patients with primary bacteremia
(42.9%) or pneumonia (23.7%) and lowest in
patients with urinary tract infection (4.5%).
Chronic pulmonary disease was significantly
more prevalent among patients who died compared to those who survived (p = 0.004). In
addition, patients who died were significantly
more likely to reside in the ICU, require
mechanical ventilation, or have severe sepsis/
septic shock at infection onset (Table 1). There
were no associations between 30-day mortality
and early active antibiotic therapy, early ceftazidime–avibactam, nor the use of combination therapy in univariate analyses. Patients

who died were significantly more likely to have
their ceftazidime–avibactam dose adjusted for
decreased renal function (72.2% vs. 42.9% in
non-survivors vs. survivors, respectively). The
median ICS, PBS, and qPitt were significantly
higher in patients who died compared to those
who survived (Table 1).
Discrimination for 30-day mortality for the
ICS, PBS, and qPitt was 0.704, 0.689, and 0.685,
respectively (Fig. 1; Table 2). No significant differences in discrimination were found for all
pairwise comparisons (Supplementary Appendix 2). All models showed adequate calibration
for 30-day mortality according to the Hosmer–Lemeshow goodness-of-fit test (Table 2).
Precision, as measured by the Brier score, ranged
from 0.128 for the ICS score to 0.132 for the
qPitt score for 30-day mortality.
The performance characteristics of the ICS,
PBS, and qPitt as binary classification tools for
30-day mortality at selected cut-points are
summarized in Table 3. Using an ICS cutoff C 11 to indicate high mortality risk provided the best performance with a sensitivity,
specificity, PPV, NPV, PLR, and NLR of 72.2%,
60.4%, 26.5%, 91.7%, 1.82, and 0.46, respectively. ICS C 11 was significantly associated
with 30-day mortality (RR 3.184, 95% CI
1.35–8.930). The post-test probability of mortality increases from 16.5% to 26.5% and
decreases from 16.5% to 8.2% among patients
with ICS C 11 and \ 11, respectively. The optimal cutoff scores to indicate high 30-day mortality risk for the PBS and qPitt were C 3
and C 2, respectively. The RR of mortality was
3.068 (95% CI 1.094–8.606) and 2.850 (95% CI
1.016–7.994) for patients with PBS C 3 and
qPitt C 2, respectively. RRs and 95% CIs for the
individual components of each score are shown
in Supplementary Appendix 3. Although the

Table 2 Risk score discrimination, calibration, and precision for 30-day mortality
Score

Discrimination C statistic
(95% CI)

Calibration Hosmer–Lemeshow
P value

Precision
Brier score

INCREMENT-CPE

0.7039 (0.5848–0.8230)

0.771

0.128

Pitt bacteremia

0.6893 (0.5709–0.8076)

0.238

0.131

QPitt score

0.6847 (0.5671–0.8023)

0.599

0.132
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Table 3 Risk score performance characteristics for 30-day mortality at selected cut-points
Patients,
n (%)

Sensitivity
(%)

Speciﬁcity
(%)

PPV
(%)

NPV
(%)

PLR

NLR

AUC (95% CI)

INCREMENT-CPE
ICS C 3

106 (97.2)

100.0

3.3

17.0

100.0

1.03

0

0.516 (0.373–0.660)

ICS C 6

91 (83.5)

100.0

19.8

19.8

100.0

1.25

0

0.599 (0.472–0.726)

ICS C 8

67 (61.5)

83.3

42.9

22.4

92.9

1.46

0.39

0.631 (0.501–0.761)

ICS C 11a

49 (45.0)

72.2

60.4

26.5

91.7

1.82

0.46

0.663 (0.529–0.798)

ICS C 12

24 (22.0)

38.8

81.3

29.2

87.1

2.07

0.75

0.601 (0.449–0.753)

ICS C 15

18 (16.5)

33.3

86.8

33.3

86.8

2.52

0.77

0.601 (0.447–0.755)

Pitt bacteremia score
PBS C 1

78

94.4

33.0

21.8

96.8

1.41

0.17

0.637 (0.514–0.760)

PBS C 2

69

88.8

41.8

23.2

95.0

1.53

0.27

0.653 (0.529–0.777)

PBS C 3a

50

72.2

59.3

26.0

91.5

1.77

0.47

0.658 (0.523–0.793)

PBS C 4

45

61.1

62.6

24.4

89.0

1.63

0.62

0.619 (0.476–0.762)

PBS C 5

31

50.0

75.8

29.0

88.5

2.07

0.66

0.629 (0.481–0.777)

PBS C 6

24

38.9

81.3

29.2

87.1

2.08

0.75

0.601 (0.449–0.753)

PBS C 7

13

11.1

87.9

15.3

83.3

0.92

1.01

0.505 (0.359–0.651)

PBS C 8

7

11.1

94.5

28.6

84.3

2.02

0.94

0.528 (0.377–0.679)

qPitt score
qPitt C 1

79 (72.5)

94.4

31.9

21.5

96.7

1.39

0.18

0.632 (0.508–0.755)

qPitt C 2a

52 (47.7)

72.2

57.1

25.0

91.2

1.68

0.49

0.647 (0.511–0.782)

qPitt C 3

24 (22.0)

38.9

81.3

29.2

87.1

2.08

0.75

0.601 (0.449–0.753)

AUC area under the receiver operator characteristic curve, CI conﬁdence interval, NLR negative likelihood ratio, NPV
negative predictive value, PLR positive likelihood ratio, PPV positive predictive value
a
J (sensitivity ? speciﬁcity - 1 is maximized)
confidence intervals were wide, all components
of the ICS had RRs [ 2. With regard to the
components of the PBS and qPitt, altered mental status and respiratory failure/mechanical
ventilation consistently had RRs [ 2, while the
association between temperature and mortality
was variable. Survival curves for the dichotomized ICS, PBS, and qPitt are shown in
Fig. 2a–c. Early and sustained separation
between curves was seen for all scores, and the
log rank tests were significant for ICS C 11 and
PBS C 3 (p = 0.0315 and p = 0.0242, respectively) but not qPitt C 2 (p = 0.0521).

No significant associations between 30-day
mortality and early active, early ceftazidime–avibactam,
combination
ceftazidime–avibactam
therapy
nor
ceftazidime–avibactam renal dose adjustment
were found after controlling for each risk score
(data not shown).

DISCUSSION
We conducted a retrospective, multicenter
study evaluating the predictive performance of
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Fig. 2 Survival curves for a INCREMENT-CPE C 11
vs. \ 11, b Pitt Bacteremia score C 3 vs \ 3 and
c qPitt C 2 vs. \ 2. ICS log-rank p = 0.0315. PBS log

rank p = 0.0242. qPitt log rank p = 0.0521. ICS INCREMENT-CPE score, PBS: Pitt Bacteremia score

Infect Dis Ther

the ICS, PBS, and qPitt for mortality in patients
with CRE infections treated with ceftazidime–avibactam. Overall, the scoring systems demonstrated adequate calibration and
precision in our cohort. According to conventional thresholds to categorize score discrimination [16, 17], the ICS demonstrated
satisfactory discrimination while the PBS and
qPitt had poor discrimination. However, differences between scores were very small and not
statistically significant.
RCTs to help guide treatment selection for
patients with CRE infections are scarce. Most
available clinical studies are observational and
retrospective with important limitations,
including selection bias and inadequate control
for confounding. Risk scores are useful for confounding adjustment when analyzing observational data. However, they may perform less
well in external cohorts, and, although a model
may be successful at one point in time,
antimicrobial resistance patterns, pathogen
virulence, and standards of care change with
time and therefore models must be updated.
Our findings do not fully align with those of
Henderson et al., who evaluated the performance of the PBS and qPitt for 14-day mortality
in 475 patients with non-bacteremic and bacteremic CRE infections from the CRACKLE-1
database [7]. In their evaluation, the discriminatory ability of the PBS and qPitt was considerably higher than in our cohort (0.853 and
0.851, respectively). With regard to the ICS,
which was recently validated in 42 patients with
non-bacteremic and bacteremic K. pneumoniae
carbapenemase-producing K. pneumoniae infections, 30-day mortality was substantially higher
than in our cohort (57.1% vs. 16.5%), but discrimination was similar (AUC 0.78 vs. 0.70).
The optimal cut-point to identify patients at
high risk for 30-day mortality was 11 in our
cohort versus 8 in the validation study by Cano
et al. [6].
Several factors may account for these discrepancies. First, there are important differences
between the cohorts with regard to infection
source (less bacteremia and more respiratory in
our cohort) and pathogen species (more diverse
in this study vs. primarily K. pneumoniae in the
other studies). It is notable, however, that

Henderson et al. found the performance of the
PBS and qPitt to be similar when analyses were
restricted to the subgroup of patients with nonbacteremic CRE infections [7]. Furthermore, an
important property of the most useful scoring
systems is that they perform similarly across
different target populations. Second, patients
who died within 72 h of infection onset were
excluded from our study (patients had to
receive C 72 h of ceftazidime–avibactam), and
variables such as severe sepsis/septic shock may
best predict very early versus later deaths.
However, observational studies evaluating
antibiotic alternatives typically have inclusion
criteria based on receipt of C 48–72 h of the
antibiotics of interest [9, 22, 23]. Prediction
scores that discriminate for later deaths may be
more suited for adjustment in these studies. The
ICS was developed and validated specifically in
patients with CPE infections. We did not confirm carbapenemase production, and a proportion of patients were likely infected with noncarbapenemase-producing CRE which have
been shown to confer a lower risk of poor outcomes compared to CPE [24]. However, as was
the case in our study, these data are not always
available for observational analyses.
As noted previously, the validation studies
for the ICS, PBS, and qPitt were conducted largely in the era before the introduction of newer
antibiotics with activity against CRE [6, 7]. Two
recent observational studies found improved
survival in patients with CRE infection treated
with ceftazidime–avibactam compared to historical controls treated with colistin-, aminoglycoside-, and carbapenem-based regimens
[8, 9]. It is plausible that the use of ceftazidime–avibactam in all patients in our cohort
may have partly contributed to the observed
differences in score performance. However, it is
important to remember that other changes have
occurred in recent years that may have influenced the relationship between baseline variables and outcomes. Rapid genomic and
phenotypic methods are now available to
accelerate the identification of CRE [25]. A great
deal of progress has also been made with regard
to our understanding of key aspects of the
complex pharmacokinetics of polymyxins
enabling the design of dosing regimens more
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likely to achieve therapeutic concentrations
[26]. Ten percent of patients in this study
received a polymyxin with ceftazidime–avibactam. Furthermore, at most institutions, the use
of new antibiotics must be approved by the
antimicrobial stewardship team or infectious
diseases consult service. All patients in our
study were managed by the infectious diseases
consult service. The value of specialist involvement in the management of multidrug-resistant
infections is well established [27–31].
The PBS and qPitt scores are based on the
important severity of illness-related variables,
while the ICS also adds comorbidities and site of
infection. None of the scores incorporate key
treatment-related factors that could influence
outcomes. We observed that mortality was significantly higher in patients who had their ceftazidime–avibactam dose renally adjusted. The
association was no longer significant after
adjustment based on the scores, raising the
possibility that need for dose adjustment may
be a surrogate for other prognostic variables.
Renal impairment and the need for renal
replacement therapy have been identified by
other investigators as risk factors for poor outcomes in patients treated with ceftazidime–avibactam [32–34] Antibiotic blood and tissue
concentrations as well as minimum inhibitory
concentrations may impact patient response,
and inclusion in prognostic modeling could
improve predictive performance at the expense
of model simplicity. Conversely, it may be
worthwhile to revisit and revise protocols pertaining to ceftazidime–avibactam renal dose
adjustment criteria [35].
Our study has several important limitations.
First, the study is subject to inherent bias with
its retrospective, observational design. However, in-depth EMR reviews allowed us to obtain
detailed patient level data that may not be
available in validation studies that obtain data
from large healthcare administrative databases.
Second, although our data spanned 4 years and
we enrolled patients from six medical centers,
the number of patients included was relatively
small owing to the infrequency of CRE infections and slow incorporation of new antibiotics
into clinical practice. Our event rate was also
low, which may partly explain the variable

performance of the models. We calculated the
scores using the worst physiological measurements within 24 h of culture collection as a
proxy for infection onset. However, for patients
with community-onset infections as well as
those with chronic relapsing infections, the
time-frame used may not have reflected the true
infection onset. We included only patients
treated with ceftazidime–avibactam. Evaluations of scoring system performance in patients
treated with other novel agents would be
valuable.

CONCLUSION
There is an ongoing trend in infectious diseases
toward algorithmic approaches for risk stratification and treatment. With respect to clinical
use, the ICS, PBS, and qPitt all have the advantages of being based on readily available variables and being simple to calculate compared to
the more time-intensive APACHE II or SOFA
scores. However, none performed well enough
in our cohort to be used for clinical decisionmaking in individual patients. Updating the
scores to more accurately predict outcomes in
the era of novel antibiotics, rapid diagnostics,
and infectious diseases specialist involvement
would be worthwhile, not only to improve their
utility as tools in observational research but also
so that clinicians can use them as supplementary information when making appropriate
decisions about the management of patients
with CRE infections.
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